OpGen (NASDAQ:OPGN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a research note released on Monday. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

Shares of NASDAQ OPGN opened at $1.54 on Monday. OpGen has a one year low of $1.40 and a one year high of $9.90. The business has a 50-day moving average price of $1.80 and a two-hundred day moving average price of $2.38.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.